Clinical Trials Logo

Clinical Trial Summary

A retrospective analysis was conducted on RAIR-DTC patients who underwent radioactive 125I seed implantation from January 2015 to February 2022 at Jiangxi Cancer Hospital. Prescription dose: 80~120 Gy. All cases were followed up at 1, 3, and 5 months postoperatively to monitor changes in tumor size, serum thyroglobulin (Tg), and serum anti-thyroglobulin antibody levels in thyrotropin-inhibited states, pain scores, and postoperative adverse reactions. The data were processed and analyzed using IBM SPSS 26.0. Pairwise comparisons were conducted using the Wilcoxon signed-rank test, and a p-value of less than 0.05 indicated statistical significance.


Clinical Trial Description

Data from RAIR-DTC patients hospitalized at Jiangxi Cancer Hospital from January 2015 to February 2022 were retrospectively collected. In advance of the surgery, patients were informed about their condition, the expected efficacy of 125I seed implantation therapy, alternative treatments such as external beam radiotherapy and chemotherapy, as well as potential side effects and toxic effects. The preoperative evaluation process includes assessments of coagulation function, liver and kidney function, cardiopulmonary function, and local CT scans. A collaborative effort between physicians and physicists was undertaken to establish a treatment regimen with a prescription dose ranging from 80 to 120 Gy. The patient accepted the treatment plan and signed an informed consent form. The CT-guided 125I seed implantation procedure was conducted according to the prescribed treatment regimen. Efficacy evaluations were conducted at pre-surgery, 1-, 3-, and 5-month post-surgery. The evaluations focused on lesion dimensions, serum thyroglobulin (Tg), TG antibodies (TGAb), thyroid-stimulating hormone (TSH) levels, pain levels, and adverse reactions. Lesion size was determined using CT imaging. Lymph nodes were assessed based on their shortest diameter, while other target lesions were evaluated based on their longest diameter. Each measurable lesion underwent an average measurement derived from a minimum of three readings, with all measurements conducted by the same individual to minimize measurement discrepancies. Response Evaluation Criteria in Solid Tumors (RECIST 1.1) [1] were used to assess treatment response. Use the Visual Analogue Scale to record patients' pain scores. Postoperative adverse reactions, including infection, bleeding, pneumothorax, bone marrow suppression, and seed displacement, were recorded. Radiation injury was graded according to the Radiation Therapy Oncology Group (RTOG) and European Organization for Research and Treatment of Cancer (EORTC) toxicity criteria [2]. The data were analyzed using IBM SPSS 26.0. The count data (n%) and skewed measures [Md (Q1, Q3)] are presented. Group comparisons were conducted using the paired Wilcoxon rank-sum test, with statistical significance set at P < 0.05. This study was approved by the Ethics Committee of Jiangxi Provincial Cancer Hospital. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06362772
Study type Observational
Source Jiangxi Provincial Cancer Hospital
Contact
Status Completed
Phase
Start date January 1, 2015
Completion date April 1, 2023

See also
  Status Clinical Trial Phase
Completed NCT00537095 - Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer Phase 2
Recruiting NCT04139096 - Genetic Susceptibility to Radiation Induced Thyroid Cancer
Completed NCT00754182 - Subcuticular Suture Versus Synthetic Glue in Thyroidectomy Incision N/A
Completed NCT00094055 - Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer Phase 2
Completed NCT00148213 - Clinical Evaluation of a New Highly Sensitive Thyroglobulin Assay in Differentiated Thyroid Carcinoma N/A
Recruiting NCT06398795 - Dual-port Trans-subclavian Thyroid Endoscopic Surgery N/A
Recruiting NCT01005654 - Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
Active, not recruiting NCT05579782 - Assessing Benefits of NIRAF Detection for Identifying Parathyroid Glands During Total Thyroidectomy N/A
Completed NCT01437254 - To Compare Safety and the General Imaging Pattern of Cyclotron Produced Technetium vs. Generator Produced Technetium in Patients With Thyroid Cancer Phase 1
Recruiting NCT03160274 - Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
Completed NCT00984282 - Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer Phase 3
Completed NCT01292044 - The Role of Elastography in the Diagnosis of Thyroid Nodules N/A
Terminated NCT04644315 - A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors Phase 2
Active, not recruiting NCT02418247 - Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer Phase 2/Phase 3
Completed NCT00467506 - Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma Phase 2
Completed NCT02430714 - Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)
Recruiting NCT04396912 - Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: STROBE - Guided Prospective Cohort
Enrolling by invitation NCT04411290 - Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases
Recruiting NCT04410601 - Post-thyroidectomy Dysphagia: An International Multicentric CONSORT - Compatible RCT N/A
Completed NCT03469310 - Minimizing Narcotic Analgesics After Endocrine Surgery Phase 4